Omnitarg (Breast Cancer) Analysis and Forecasts to 2020


#28315

52pages

GlobalData

$ 2000

In Stock

 

GlobalDatas pharmaceuticals report, Omnitarg (Breast Cancer) Analysis and Forecasts to 2020 provides Omnitarg sales estimates for US, and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

 

Scope

 

  • Therapy area profile including patient population for the US, and EU5 (six major markets)
  • Analysis and review of Omnitarg including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Omnitarg including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2002-2020 for Omnitarg in the six major markets

 

Reasons to buy

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

 

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 5
2.1 Breast Cancer Market 5
2.2 Epidemiology 5
2.3 GlobalData Report Guidance 7


3 Breast Cancer: Market Characterization 8
3.1 Breast Cancer Market 8
3.2 Breast Cancer Market Forecasts and CAGR 8
3.3 Drivers of Breast Cancer Market 9
3.3.1 High Prevalence 9
3.3.2 Breast Cancer: Most Frequent Cancer in Women 9
3.3.3 Increasing Breast Cancer Incidence Rate 10
3.3.4 Decreasing Breast Cancer Mortality Rate 13
3.3.5 High Survival Rates of Breast Cancer 15


4 Staging of Breast Cancer: Introduction 16
4.1 Distribution of Patients by Stages 16
4.1.1 Stages 16


5 Predictive Biomarker in the Treatment of Breast Cancer 20


6 Treatment options of Breast Cancer 22
6.1 Stage 0 Breast Cancer: Treatment Options 22
6.2 Early Stage Breast Cancer (Excluding Stage 0) 23
6.3 Metastatic Breast Cancer (MBC) 25
6.3.1 Endocrine treatment: Adjuvant, First Line and Second Line 25
6.3.2 Cytotoxic Chemotherapy 27
6.3.3 Management of Patients with HER-2 Positive Patients 29


7 Omnitarg 31
7.1 Introduction 31
7.2 Mechanism of Action 31
7.3 Clinical Studies 32
7.4 Sales Drivers 32
7.4.1 Breast Cancer Market 32
7.4.2 Effective Mechanism of Action 32
7.4.3 Better Efficacy 32
7.5 Drug Risk Benefit Score 33
7.6 Intensity of Competition 34
7.7 Sales forecasts of Omnitarg 34
7.7.1 Target patient pool of Omnitarg 34
7.7.2 Market Penetration 35
7.7.3 Dosing 36
7.7.4 Annual Cost of Therapy 36
7.7.5 Sales Projections of Omnitarg 36


8 Breast Cancer Market: Appendix 46
8.1 Market Definitions 46
8.2 Abbreviations 46
8.3 Research Methodology 47
8.3.1 Coverage 47
8.3.2 Secondary Research 47
8.3.3 Forecasting 48
8.3.4 Number of Patients Approved to take the Drug 48
8.3.5 Net Penetration of Drug 48
8.3.6 Net Annual Dosing 50
8.3.7 Annual Cost of Therapy 50
8.3.8 Primary Research 50
8.3.9 Expert Panels 50
8.4 Contact Us 51
8.5 Disclaimer 51
8.6 Sources 52


Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030 5
Table 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 9
Table 3: Five-Year Relative Survival Rates, By Stages 15
Table 4:Omnitarg Clinical Trials 32
Table 5:Drug Risk Benefit Score (DRB)Omnitarg, Herceptin and docetaxel combination 33
Table 6:Comparison with major competitors 34
Table 7:Omnitarg, Breast Cancer, Global Sales Forecasts ($m), 20142020 37
Table 8:Omnitarg, Breast Cancer, The US Sales Forecasts ($m), 20142020 38
Table 9:Omnitarg, Breast Cancer, The UK Sales Forecasts ($m), 20142020 39
Table 10:Omnitarg, Breast Cancer, France Sales Forecasts ($m), 20142020 40
Table 11:Omnitarg, Breast Cancer, Germany, Sales Forecasts ($m), 20142020 41
Table 12:Omnitarg, Breast Cancer, Italy, Sales Forecasts ($m), 20142020 42
Table 13:Omnitarg, Breast Cancer, Spain, Sales Forecasts ($m), 20142020 43
Table 14:Omnitarg, Breast Cancer, Japan, Sales Forecasts ($m), 20142020 44


Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 6
Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 8
Figure 3: Top 10 Most Frequent Cancers on Incidence-Mortality Matrix, Worldwide, 2010 10
Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 11
Figure 5: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 11
Figure 6: Breast Cancer, Incidence, Worldwide, 2008-2030 12
Figure 7: All Cancers, Incidence, Worldwide, 2008-2030 12
Figure 8: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 13
Figure 9: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 13
Figure 10: Breast Cancer, Mortality, Worldwide, 2008-2030 14
Figure 11: All Cancers, Mortality, Worldwide, 2008-2030 14
Figure 12: Broad Classification of Breast Cancer, By Type 16
Figure 13: Classification of Non-Invasive Breast Cancer, By CIS 16
Figure 14: Classification of Invasive Breast Cancer, By Stages 17
Figure 15: Classification of Invasive Breast Cancer, By Treatment 17
Figure 16: Classification of Metastatic or Advanced Breast Cancer 18
Figure 17: Classification of Early Stage Breast Cancer (Excluding Stage 0) 18
Figure 18: Classification of Locally Advanced Breast Cancer 18
Figure 19: Metastatic Breast Cancer Classification 19
Figure 20: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer 20
Figure 21: Breast Cancer Intrinsic Sub Types used for deciding Treatment Options for MBC 21
Figure 22: Breast Cancer Types in Decreasing Order of their Aggressiveness 21
Figure 23: Treatment Options, DCIS Breast Cancer 22
Figure 24: Treatment Options, LCIS Breast Cancer 23
Figure 25: Treatment Options, Stages I, II and IIIA 23
Figure 26: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer) 24
Figure 27: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer) 24
Figure 28: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer) 25
Figure 29: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer 26
Figure 30: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC 26
Figure 31: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer 28
Figure 32: Treatment Options, HR Negative and HER2 Positive Metastatic Breast Cancer 29
Figure 33:Mechanism of Action 31
Figure 34:Drug Model Diagram of Omnitarg 35
Figure 35:Omnitarg, Breast Cancer, Global Sales Forecasts ($m), 20142020 37
Figure 36:Omnitarg, Breast Cancer, The US Sales Forecasts ($m), 20142020 38
Figure 37:Omnitarg, Breast Cancer, The UK Sales Forecasts ($m), 20142020 39
Figure 38:Omnitarg, Breast Cancer, France Sales Forecasts ($m), 20142020 40
Figure 39:Omnitarg, Breast Cancer, Germany, Sales Forecasts ($m), 20142020 41
Figure 40:Omnitarg, Breast Cancer, Italy, Sales Forecasts ($m), 20142020 42
Figure 41:Omnitarg, Breast Cancer, Spain, Sales Forecasts ($m), 20142020 43
Figure 42:Omnitarg, Breast Cancer, Japan, Sales Forecasts ($m), 20142020 44
Figure 43 :Omnitarg, Breast cancer Global ,Sales Forecasts ($m), 2020 45
Figure 44:Drug Model Diagram 49
Figure 45:Patients Approved for the Drug 49